Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A
about
Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3ABedaquiline: a review of human pharmacokinetics and drug-drug interactionsPharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsIsoniazid metabolism and hepatotoxicityPharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patientsNetwork neighbors of drug targets contribute to drug side-effect similarityAssociation of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean SubjectsInsights into the pharmacokinetic properties of antitubercular drugs.Summary of information on human CYP enzymes: human P450 metabolism data.Using genotyping to delineate tuberculosis transmission in long-term care facilities: single facility 4-year experienceComparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.Adverse reactions to first-line antituberculosis drugs.Isoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin NProtective effects of metallothionein on isoniazid and rifampicin-induced hepatotoxicity in mice.Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.Regular Sputum Check-Up for Early Diagnosis of Tuberculosis after Exposure in Healthcare Facilities.TB and HIV Therapeutics: Pharmacology Research Priorities.Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine MedicationLuminogenic cytochrome P450 assays.Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury.Molecular pharmacokinetics of catharanthus (vinca) alkaloids.Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients.CYP2C19 drug-drug and drug-gene interactions in ED patients.Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failureCYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicinThe influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosisA Toxicologist's Guide to the Preclinical Assessment of Hepatic Microsomal Enzyme Induction.Pharmacogenetics of drug-induced liver injury.Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs.In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.The challenges of pharmacokinetic variability of first-line anti-TB drugs.Treatment of Comorbid Tuberculosis and Depression.NAT2 gene polymorphism: covert drug interaction causing phenytoin toxicity.
P2860
Q24317436-ECF47240-3ABF-42CE-BE8E-919EAA31F517Q26864991-8203FF83-B94E-4113-8ACB-8EFA1DA6BE1BQ28069383-1FED8733-C9BF-47D3-BA04-5D3062A8DF25Q28076859-D68C9691-7C5A-4462-8E44-2B2275FE18D3Q28478275-CFA23D3B-82C8-4081-AA57-DD42EC9A7F84Q28479003-12829E6E-FDA1-43A0-B65C-BD8878AFFF12Q29308187-6E98F386-70E8-48C7-8F67-08A045580E56Q30251497-A61D0398-3F42-4DF2-9EA7-94F5317B065EQ32103802-57C3EBE7-9CED-4086-B1DA-FCFC222956C3Q33795832-0E3B331F-F6E1-4572-A707-FE8FD986D3BCQ33797986-74C19B83-A4DF-4CED-A586-59C0C814C5BEQ34193050-0F38FD77-44DF-4D3B-8C9C-1CF4372C9BCAQ34251459-F13A985A-5A82-4C7C-8550-8B78C764FA09Q34497890-88D8FB1B-5B1A-4449-AE5F-2DED97A592DCQ34924586-8DB4632E-D2F5-492A-997D-ABC315B14971Q34964833-E718D164-DFDC-45F0-AF6B-8F605DCF9008Q35065871-EFE816EA-84FE-46FD-B75C-AD16FDA7589AQ35518558-DC937E43-ADA3-4949-A374-E0B4D522CB92Q35827548-2E9D3200-8ED0-4F5D-9491-AF71AF6F5E1AQ36040016-6DFF8939-BAC0-44E3-950B-6AC636CD93FCQ36099838-971D8B51-055B-4A95-ABF3-E17B8600187FQ36247566-523BF38F-C468-4DD3-80B9-88B6A7B61700Q36543124-0F71D2E2-764E-4EC3-AD6E-2FD7FF131D6BQ36725202-100FC779-96CF-43A5-B39E-2D4A8C3ABE3EQ36795140-2BC63A68-9982-4130-B374-4A7730D0F351Q36830922-F4F15DD9-ED75-4911-A4CC-FFF830B449B3Q36930041-07A4CEC7-1C7C-4553-8D1F-2070C23BFBA7Q36998032-93080907-8183-48C9-8441-07CC425663F4Q37082852-93D976F7-D091-4892-915C-A7E5C514879FQ37184431-29EDE88D-A1C2-4EF2-BD55-48833634AD1CQ37369323-4FAABF68-E586-44D5-B832-50E099A9CA66Q37466856-DE8A8AA4-69AA-41D5-8B13-BCE971171AAFQ37658729-79E58448-B292-45A8-BBD2-5D54FE127CA0Q37770487-FDE82FC8-8746-40DF-A5CC-A0F2365DF14AQ37810480-4458EDAD-47A2-4465-8A8B-CB1F74FD0E13Q37989979-21619DA9-237E-4490-8CFD-DE1BD24E3AD7Q38874266-C2ECC210-E9E5-45EE-9817-13F8111F4DD6Q38977166-C56BA20E-511C-40F1-8D8D-5E6B542D4295Q39853786-1D6BC42F-E650-4161-9272-1894773806F5Q41675062-87A80F9E-A540-4A14-A718-4F73CD1D88C9
P2860
Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Inhibition of cytochrome P450 ...... nhibition of CYP2C19 and CYP3A
@ast
Inhibition of cytochrome P450 ...... nhibition of CYP2C19 and CYP3A
@en
Inhibition of cytochrome P450 ...... nhibition of CYP2C19 and CYP3A
@nl
type
label
Inhibition of cytochrome P450 ...... nhibition of CYP2C19 and CYP3A
@ast
Inhibition of cytochrome P450 ...... nhibition of CYP2C19 and CYP3A
@en
Inhibition of cytochrome P450 ...... nhibition of CYP2C19 and CYP3A
@nl
prefLabel
Inhibition of cytochrome P450 ...... nhibition of CYP2C19 and CYP3A
@ast
Inhibition of cytochrome P450 ...... nhibition of CYP2C19 and CYP3A
@en
Inhibition of cytochrome P450 ...... nhibition of CYP2C19 and CYP3A
@nl
P2093
P2860
P3181
P1476
Inhibition of cytochrome P450 ...... nhibition of CYP2C19 and CYP3A
@en
P2093
D A Flockhart
N V Soukhova
P2860
P304
P3181
P356
10.1128/AAC.45.2.382-392.2001
P407
P577
2001-02-01T00:00:00Z